AR095668A1 - Toxinas de clostridium difficile, composiciones y métodos de purificación de las mismas - Google Patents

Toxinas de clostridium difficile, composiciones y métodos de purificación de las mismas

Info

Publication number
AR095668A1
AR095668A1 ARP140101274A ARP140101274A AR095668A1 AR 095668 A1 AR095668 A1 AR 095668A1 AR P140101274 A ARP140101274 A AR P140101274A AR P140101274 A ARP140101274 A AR P140101274A AR 095668 A1 AR095668 A1 AR 095668A1
Authority
AR
Argentina
Prior art keywords
toxins
methods
disclosed
compositions
toxoids
Prior art date
Application number
ARP140101274A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095668(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of AR095668A1 publication Critical patent/AR095668A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
ARP140101274A 2013-03-15 2014-03-18 Toxinas de clostridium difficile, composiciones y métodos de purificación de las mismas AR095668A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361793376P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR095668A1 true AR095668A1 (es) 2015-11-04

Family

ID=50489432

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101274A AR095668A1 (es) 2013-03-15 2014-03-18 Toxinas de clostridium difficile, composiciones y métodos de purificación de las mismas

Country Status (13)

Country Link
US (1) US20160030542A1 (enExample)
EP (1) EP2970400A1 (enExample)
JP (1) JP2016519671A (enExample)
KR (1) KR20150133771A (enExample)
CN (1) CN105308066A (enExample)
AR (1) AR095668A1 (enExample)
AU (2) AU2014228983B2 (enExample)
BR (1) BR112015023469A8 (enExample)
CA (1) CA2907156A1 (enExample)
HK (1) HK1213917A1 (enExample)
SG (1) SG11201507578PA (enExample)
TW (1) TW201518316A (enExample)
WO (1) WO2014144594A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510166YA (en) * 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
CN108003224A (zh) * 2017-12-20 2018-05-08 天康生物股份有限公司 一种多杀性巴氏杆菌毒素蛋白的纯化方法
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
AU2008280755B9 (en) 2007-07-26 2014-09-25 Sanofi Pasteur Limited Antigen-adjuvant compositions and methods
WO2009035707A1 (en) 2007-09-14 2009-03-19 Acambis Inc. Pharmaceutical compositions containing clostridium difficile toxoids a and b
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Also Published As

Publication number Publication date
BR112015023469A2 (pt) 2017-07-18
HK1213917A1 (zh) 2016-07-15
TW201518316A (zh) 2015-05-16
US20160030542A1 (en) 2016-02-04
EP2970400A1 (en) 2016-01-20
KR20150133771A (ko) 2015-11-30
WO2014144594A8 (en) 2014-11-13
BR112015023469A8 (pt) 2019-12-03
AU2018204879A1 (en) 2018-07-26
WO2014144594A1 (en) 2014-09-18
AU2014228983B2 (en) 2018-04-05
AU2014228983A1 (en) 2015-10-08
CN105308066A (zh) 2016-02-03
JP2016519671A (ja) 2016-07-07
SG11201507578PA (en) 2015-10-29
CA2907156A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
BR112018008901A8 (pt) formulações subcutâneas de anticorpos anti-cd 38 e seus usos
BR112016013562A2 (pt) Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
MX367521B (es) Composiciones de insulina de rápida acción.
MX2016000047A (es) Neurotoxinas cationicas.
SG10201808151RA (en) Cortistatin analogues and syntheses and uses thereof
BR112017009467A2 (pt) composição de limpeza
CO6751260A2 (es) Vacunas basadas en omv contra infecciones por burkholderia
BR112013005855A2 (pt) heteroarilas fundidas e seus usos
AR095668A1 (es) Toxinas de clostridium difficile, composiciones y métodos de purificación de las mismas
PE20151978A1 (es) Composiciones nutricionales que contienen un componente peptidico con propiedades antinflamatorias y usos del mismo
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
CR20150314A (es) Pirimido-[4,5-b]-quinolina-4,5 (3h, 10h)-dionas como supresoras de mutación sin sentido
AR095669A1 (es) Toxinas, composiciones y métodos relacionados
BR112016001876A2 (pt) composto de benzoxaborol tricíclico, método de preparação e uso do mesmo
BR112018004861A2 (pt) processo para purificação de hidrolisado de biomassa
BR112018069079A2 (pt) construtos de alfavírus vivos atenuados e métodos e usos dos mesmos
BR112015032388A8 (pt) glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições
MX2018007992A (es) Producto para el cuidado bucal y metodos para uso y fabricacion de este.
MX389969B (es) Colores para antehogar libres de niquel y libres de cromo para tanques de vidrio.
BR112017018707A2 (pt) composições compreendendo compostos de mentol como agentes suavizantes
EP4505880A3 (en) Stevia extracts
BR112016019893A2 (pt) composições de glicoproteína sialilada e seus usos
IN2014CH01392A (enExample)

Legal Events

Date Code Title Description
FB Suspension of granting procedure